Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): early-phase trial registry
3 of 4 indexed Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): 4 US clinical trials tracked, 3 recruiting.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Takeda, running 3 of these trials.
Enrollment posture brief
Registry condition chronic-inflammatory-demyelinating-polyradiculoneuropathy-cidp
OPEN 3 | RECR 75% | LATE 1 | EARLY 2 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
NCT06747351
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
NCT06798012
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
Takeda
NCT06538064
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
UCB Biopharma S.P.R.L.
NCT03861481
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Takeda sponsors the most Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials on record, review their full trial history before evaluating a specific study. See Takeda's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) condition card totals 4 registered trials; most-linked intervention Rozanolixizumab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.